Skip to main content

Supernus, Inc.

corporate_fare Company Profile

Supernus, Inc.

INDV·NASDAQ·Life Sciences·CIK 0001625297

Indivior Pharmaceuticals, Inc. is a market leader in long-acting injectable medications for opioid use disorder (OUD). The company focuses on providing evidence-based drug therapies for OUD and aims to improve understanding of OUD as a chronic, relapsing, but treatable brain disease. For over 25 years, Indivior has innovated in addiction medicine, creating distinct therapeutic solutions that support patient recovery, increase access to care, and provide value for patients, healthcare systems, and stockholders. Indivior is headquartered in Richmond, Virginia, U.S. Indivior's product portfolio is primarily available in the U.S., with additional products in Canada, Australia, France, and Germany. Its core approved treatments for OUD include SUBLOCADE (buprenorphine extended-release monthly injection) and SUBOXONE Film (buprenorphine and naloxone sublingual film). Product availability, including dosage, strength, and indication, varies across these countries. The U.S. is Indivior's core geographic market, based on where sales originate, and accounted for 85% of net revenues for the year ended December 31, 2025, 85% for 2024, and 83% for 2023. In the U.S., the company sells only SUBLOCADE and SUBOXONE Film. Indivior's business was initially a division of Reckitt Benckiser Group PLC. Indivior PLC was incorporated on September 26, 2014, to acquire this specialty pharmaceutical business unit, becoming a standalone business effective December 23, 2014. On December 11, 2025, stockholders approved a plan to change the company's domicile to the U.S.

Supernus, Inc. (NASDAQ:INDV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for INDV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for INDV spans 8-K, 10-Q, 424B3, S-4/A.

Recent high-impact activity:

  • Indivior-Supernus Merger Closes; $650M Term Loan Funds $1B Special Dividend
  • Indivior Beats Q3 Estimates With $1.32 EPS, Revenue Up 13% to $356M
  • Indivior Q3: Revenue Up 13% to $356M, Net Income $137M Ahead of Nov 2 Supernus Close
  • Indivior Posts Record Q3: SUBLOCADE $267M, EPS $1.12, Merger Closes Nov 2
  • Indivior Posts Record Q3: SUBLOCADE Up 22%, Adjusted EBITDA Margin Hits 59%

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.24B
Net Income
$210M
Diluted EPS
$1.64
Op. Cash Flow
-$27M
Free Cash Flow
-$93M
Gross Profit
$994M
Operating Income
$262M
Cash & Equivalents
$195M
Total Debt
$319M
Debt / Equity
-3.26×
Net Margin
16.9%
Shares Outstanding
125M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012237

Short Interest & Short Volume

3.63 days to cover

FINRA reported short interest of 9,523,819 shares in INDV as of the October 30, 2026 settlement, a 1.2% increase from the prior period — about 3.6 days to cover at its recent average daily volume.

Short interest (bi-monthly positions)9,523,819 shares as of October 30, 2026
Change vs prior period▲ 1.2%
Days to cover3.63 at avg daily volume of 2,620,075

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$28 -1.23% today
52-week range · as of 2026-11-02 $27.68 – $42.81
Market cap
$3.57B
Volume
2.8M (1.1× avg)
3-mo avg 2.6M
Live data · 2026-11-22 06:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed INDV - Latest Insights

INDV
Nov 02, 2026, 9:27 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $35.56
Real-time Price: $28.00 info
Change: -$7.56 (-21%) info
Market Cap: $3.571B info
INDV
Oct 29, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $35.25
Real-time Price: $28.00 info
Change: -$7.25 (-21%) info
Market Cap: $3.571B info
INDV
Oct 29, 2026, 8:14 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.51
Real-time Price: $28.00 info
Change: -$8.51 (-23%) info
Market Cap: $3.571B info
INDV
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.44
Real-time Price: $28.00 info
Change: -$6.44 (-19%) info
Market Cap: $3.571B info
INDV
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $34.44
Real-time Price: $28.00 info
Change: -$6.44 (-19%) info
Market Cap: $3.571B info
INDV
Oct 06, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Updated Oct 6, 7:18 AM ET — The 425 filing provides the same supplemental Cantor valuation disclosures as the 8-K, including Supernus implied per share range of $50.55…
Price at Filing: $35.99
Real-time Price: $28.00 info
Change: -$7.99 (-22%) info
Market Cap: $3.571B info
INDV
Sep 17, 2026, 7:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.51
Real-time Price: $28.00 info
Change: -$7.51 (-21%) info
Market Cap: $3.571B info
INDV
Sep 17, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $36.11
Real-time Price: $28.00 info
Change: -$8.11 (-22%) info
Market Cap: $3.571B info
INDV
Sep 11, 2026, 4:17 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $34.49
Real-time Price: $28.00 info
Change: -$6.49 (-19%) info
Market Cap: $3.571B info
INDV
Sep 09, 2026, 5:11 PM EDT
Filing Type: S-4/A
Importance Score:
7
Price at Filing: $34.77
Real-time Price: $28.00 info
Change: -$6.77 (-19%) info
Market Cap: $3.571B info
INDV
Aug 28, 2026, 4:56 PM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $34.87
Real-time Price: $28.00 info
Change: -$6.87 (-20%) info
Market Cap: $3.571B info
INDV
Aug 13, 2026, 5:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $38.10
Real-time Price: $28.00 info
Change: -$10.10 (-27%) info
Market Cap: $3.571B info
INDV
Aug 03, 2026, 4:24 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $37.17
Real-time Price: $28.00 info
Change: -$9.17 (-25%) info
Market Cap: $3.571B info
INDV
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $42.00
Real-time Price: $28.00 info
Change: -$14.00 (-33%) info
Market Cap: $3.571B info
INDV
Aug 03, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.56
Real-time Price: $28.00 info
Change: -$13.56 (-33%) info
Market Cap: $3.571B info
INDV
Aug 03, 2026, 6:40 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $40.67
Real-time Price: $28.00 info
Change: -$12.67 (-31%) info
Market Cap: $3.571B info
INDV
Aug 03, 2026, 6:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $40.75
Real-time Price: $28.00 info
Change: -$12.75 (-31%) info
Market Cap: $3.571B info
INDV
May 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $37.00
Real-time Price: $28.00 info
Change: -$9.00 (-24%) info
Market Cap: $3.571B info
INDV
May 15, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.30
Real-time Price: $28.00 info
Change: -$8.30 (-23%) info
Market Cap: $3.571B info
INDV
May 04, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $37.48
Real-time Price: $28.00 info
Change: -$9.48 (-25%) info
Market Cap: $3.571B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets